U.S. Nuclear Corp Portable PFAS Monitoring Devices Can Detect PFAS Down to One Part Per Trillion in Less than Two Minutes

• The EPA recently passed regulations that will require 148,000 water providers to test and treat their water for PFAS which is believed to be responsible for widespread cancers, birth defects, high cholesterol and more.

• Currently, there are no devices available for sale for this testing and all water providers must send in samples to the big labs with high costs and long times for results that can take several weeks.

• The new regulations create what is projected to be a $7.4B need for portable and accurate, and fast PFAS detection devices in the United States and probably double that for the rest of the world.

• U.S. Nuclear Corp., a long-standing company known for its’ expertise in radiation measurement recently announced their new portable PFAS detection and monitoring device that meets government requirements.

• Each unit sells for about $50,000 and demand from 148,000 municipal water districts and industrial manufacturers is projected to be $7.4B for the United States alone

• U.S. Nuclear Corp trades at 8 cents per share with a very small market cap of about $3.15 million.

 

The EPA has taken strong action designating two widely used PFAS as hazardous substances under the Superfund law, improving transparency and accountability to clean up PFAS contamination in communities.  The U.S. Environmental Protection Agency (EPA) is taking another step in its efforts to protect people from the health risks posed by exposure to “forever chemicals” in communities across the country.

​

Almost a year ago, US Nuclear Corp. (UCLE: OTCQB) revealed in a press release that they were offering portable and benchtop PFAS detection devices that are capable of determining extremely minute amounts of PFAS, PFOS and PFOA’s down to 1 part per trillion within less than 2 minutes. The units are expected to be sold for $50,000 per unit and there are now about 148,000 municipal water districts that will be required to test their water within a relatively short timeline.

​

Our research indicates that US Nuclear’s PFAS detection system is unique to the market.

​

Exposure to per-and polyfluoroalkyl substances (PFAS) has been linked to cancers, impacts to the liver and heart, and immune and developmental damage to infants and children. This final rule will designate two widely used PFAS chemicals, perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), as hazardous substances under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), also known as Superfund, and will help ensure that polluters pay to clean up their contamination.

​

This final action will address PFOA and PFOS contamination by enabling detection and cleanup of these harmful chemicals and ensuring that leaks, spills, and other releases are reported. This action builds on the recently finalized standards to protect people and communities from PFAS contamination in drinking water and represents the latest step the Biden-Harris Administration is taking to protect public health and welfare and the environment under EPA’s PFAS Strategic Roadmap and to prevent cancer before it starts through the Biden Cancer Moonshot.

​

In addition to the final rule, EPA is issuing a separate CERCLA enforcement discretion policy that makes clear that EPA will focus enforcement on parties who significantly contributed to the release of PFAS chemicals into the environment, including parties that have manufactured PFAS or used PFAS in the manufacturing process, federal facilities, and other industrial parties.

​

Conclusion

US Nuclear Corp. is a unique long-standing company that got its start from the Manhattan Project, the development of the Atomic Bomb which the recent movie Oppenheimer was all about.  Since then, US Nuclear Corp has developed a wide array of sensitive detection instruments for government and research lab use and is now branching out to broader markets with large unmet needs such as PFAS detectors that are capable of measuring PFAS in less than 4 parts per trillion which is like a grain of sand in an Olympic sized swimming pool.

​

US Nuclear also owns an interest and is partnered with the leading fusion energy and radioisotope developers, MIFTI and MIFTEC and an advanced materials company called Grapheton that is making breakthrough medical devices that can be implanted in the body that have greatly extended life spans and game changing advantages over the competition.

​

With strong and well-timed growth potential and a total market cap of about $3.15 million, and shares trading close to historic lows, US Nuclear Corp appears to be an outstanding investment consideration.

​

Legal Disclosures and Disclaimers

Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.

​

Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.

​

Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.

​

Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.

​

Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from.

​

Green Planet Microcaps was compensated $5,000 per month for this article and other services and also owns restricted shares of US Nuclear and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.

​

Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.